ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
9.87
+0.12 (1.23%)
Oct 8, 2026, 3:25 PM EDT - Market open
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $10.46 billion as of October 8, 2026. It is the 2,109th most valuable company in the world and the 747th biggest in the United States. Its market cap has increased by 342.66% in one year.
Market Cap
10.46B
Enterprise Value
11.33B
1-Year Change
342.66%
Global Rank
Country Rank
#747 United States
Category
ChartMarket Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $10.46B, a decrease of -29.43%. That is a compound annual growth rate of -6.05%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 8, 2026 | 10.46B | 436.38% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Halozyme Therapeutics | 12.69B |
| Madrigal Pharmaceuticals | 11.42B |
| Bio-Techne | 11.37B |
| BioMarin Pharmaceutical | 10.65B |
| Twist Bioscience | 9.88B |
| Vaxcyte | 9.87B |
| Krystal Biotech | 9.56B |
| Protagonist Therapeutics | 9.24B |